Trial
NCT02623582
CD123 Redirected Autologous T Cells for AML
Early Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Pennsylvania
Collaborators
—
Condition
Relapsed or Refractory Acute Myeloid Leukemia
Intervention
Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes
Why stopped
This study was terminated due to lack of funding.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-10-17